| Literature DB >> 31142546 |
Avina Sarna1, Lopamudra Ray Saraswati2, Jerry Okal3, James Matheka3, Danmark Owuor4, Roopal J Singh5, Nancy Reynolds6, Sam Kalibala7.
Abstract
BACKGROUND: We evaluated the effectiveness of a cell phone counseling intervention to promote retention in care and HIV testing of infants among women with HIV accessing prevention of mother-to-child services in Kisumu, Kenya.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31142546 PMCID: PMC6641813 DOI: 10.9745/GHSP-D-18-00241
Source DB: PubMed Journal: Glob Health Sci Pract ISSN: 2169-575X
FIGURE 1Cell Phone Counseling Protocol
FIGURE 2Flow Diagram of Participant Recruitment and Follow-Up in the Healthy Mother Healthy Baby Project in Kisumu, Kenya (2013–2016)
Abbreviation: EID, early infant diagnosis.
Baseline Characteristics of Participants Recruited in Kisumu, Kenya (2014)
| Intervention (n=207) | Control (n=197) | Total (N=404) | ||
|---|---|---|---|---|
| 24 (22, 28) | 25 (22, 29) | 25 (22, 29) | ||
| No education or adult literacy | 4/207 (1.9) | 3/197 (1.5) | 7/404 (1.7) | .72 |
| Primary/preschool | 133/207 (64.3) | 134/197 (68.0) | 267/404 (66.1) | |
| Secondary or higher | 70/207 (33.8) | 60/197 (30.5) | 130/404 (32.2) | |
| Married/cohabiting | 169/207 (81.6) | 164/197 (83.3) | 333/404 (82.4) | .31 |
| Never married | 25/207 (12.1) | 16/197 (8.1) | 41/404 (10.2) | |
| Divorced/separated/widowed | 13/207 (6.3) | 17/197 (8.6) | 30/404 (7.4) | |
| Lives by herself | 12/207 (5.8) | 14/197 (7.1) | 26/404 (6.4) | .25 |
| Lives with partner/spouse/children | 155/207 (74.9) | 157/197 (79.7) | 312/404 (77.2) | |
| Lives with other relatives/friends | 40/207 (19.3) | 26/197 (13.2) | 66/404 (16.3) | |
| Employed | 25/207 (12.1) | 39/197 (19.8) | 64/404 (15.8) | .03 |
| Not employed | 182/207 (87.9) | 158/197 (80.2) | 340/404 (84.2) | |
| Kisumu | 60/207 (29.0) | 67/197 (34.0) | 127/404 (31.4) | .28 |
| Others | 147/207 (71.0) | 130/197 (66.0) | 277/404 (68.6) | |
| 14-28 weeks | 161/207 (77.8) | 155/197 (78.7) | 316/404 (78.2) | .83 |
| 29-36 weeks | 46/207 (22.2) | 42/197 (21.3) | 88/404 (21.8) | |
| 3 (2, 4) | 3 (2, 4) | 3 (2, 4) | .38 | |
| Living, mean (SD) | 1.0 (1.5) | 1.7 (1.0) | 1.8 (1.3) | .045 |
| Dead, mean (SD) | 1.2 (1.6) | 1.4 (1.3) | 1.3 (1.5) | .34 |
| 1 year or less | 136/207 (65.7) | 132/197 (67.0) | 268/404 (66.3) | .63 |
| 2–4 years | 49/207 (23.7) | 40/197 (20.3) | 89/404 (22.0) | |
| 5 or more years | 22/207 (10.6) | 25/197 (12.7) | 47/404 (11.6) | |
| Disclosed status to partner/spouse, n/N (%) | 120/207 (58.0) | 116/197 (58.9) | 236/404 (58.4) | |
| Yes | 110/207 (53.1) | 105/196 (53.6) | 215/403 (53.4) | .93 |
| Don't know | 97/207 (46.9) | 91/196 (46.4) | 188/403 (46.7) | |
| Positive | 77/110 (70.0) | 76/105 (72.4) | 153/215 (71.2) | .70 |
| Negative | 33/110 (30.0) | 29/105 (27.6) | 62/215 (28.8) | |
| Naïve | 118/207 (57.0) | 113/197 (57.4) | 231/404 (57.2) | .94 |
| Experienced | 89/207 (43.0) | 84/197 (42.6) | 173/404 (42.8) | |
| Option A (only AZT) | 84/207 (40.6) | 84/197 (42.6) | 168/404 (41.6) | .88 |
| Option B (3 ARVs) | 123/207 (59.4) | 113/197 (57.4) | 236/404 (58.4) | |
| <350 cells/ml | 50/162 (30.8) | 53/156 (34.0) | 103/318 (32.4) | .64 |
| 351–500 cells/ml | 37/162 (22.8) | 39/156 (25.0) | 76/318 (23.9) | |
| >500 cells/ml | 75/162 (46.3) | 64/156 (41.0) | 139/318 (43.7) | |
| .38 | ||||
| <1000 copies/ml | 70/90 (77.8) | 60/72 (83.3) | 130/162 (80.3) | |
| >1001 copies/ml | 20/90 (22.2) | 12/72 (16.7) | 32/162 (19.8) | |
| Low (16–40) | 146/207 (70.5) | 135/197 (68.5) | 281/404 (69.6) | .32 |
| Moderate (41–52) | 59/207 (28.5) | 62/197 (31.5) | 121/404 (30.0) | |
| High (53–64) | 2/207 (1.0) | 0/197 (0.0) | 2/404 (0.5) | |
| No depression (<16) | 136/207 (65.7) | 107/197 (54.3) | 243/404 (60.2) | .02 |
| Sign of depression (≥16) | 71/207 (34.3) | 90/197 (45.7) | 161/404 (39.9) | |
| Good/excellent (>60) | 99/207 (47.8) | 76/197 (38.6) | 175/404 (43.3) | .06 |
| Average/poor/very poor (≤60) | 108/207 (52.2) | 121/197 (61.4) | 229/404 (56.7) |
Abbreviations: ART, antiretroviral therapy; ARV, antiretroviral; AZT, zidovudine; CD4, cluster of differentiation 4; IQR, interquartile range; PMTCT, prevention of mother-to-child transmission; SD, standard deviation.
P value is from chi-square test for discrete variables; Mann-Whitney U test for median and t test in case of means for continuous variables.
CD4 cell counts were obtained from clinic records; there are missing values due to missing records.
Viral load tests were initiated late in the course of the study, thus results are available for only some participants.
Intervention Exposure and Retention Among Intervention Participants (n=207)
| Percentage of Required Counseling Sessions Attended | Distribution of Participants Who Attended Calls (%) | Duration of Calls (minutes) | Participants Retained Until 14 Weeks Postpartum |
|---|---|---|---|
| ≤25% | 10.7 | 18.7 (19.5) | 55.6 |
| 26%–50% | 17.0 | 10.5 (4.8) | 63.3 |
| 51%–75% | 35.0 | 7.0 (2.7) | 92.7 |
| >75 | 37.4 | 7.9 (4.2) | 89.3 |
Abbreviations: ANOVA, analysis of variance; SD, standard deviation.
One way ANOVA. Differences between categories were significant at P<.001.
Chi-square test. Differences between categories were significant at P<.001.
FIGURE 3Participant Retention in Care at Delivery and 6 Weeks and 14 Weeks Postpartum, Kisumu, Kenya
Followed until delivery: intervention, 197/207; control, 153/197.
Followed until 6 weeks postpartum: intervention, 183/195; control, 137/188. Denominators exclude 17 participants total with still births (intervention, 9; control, 8) and 4 participants with infant deaths (intervention, 3; control, 1).
Followed until 14 weeks postpartum: intervention, 160/192; control, 125/188. Denominator for the intervention arm excludes 2 participants with infant deaths after 6 weeks postpartum.
Predictors of Loss to Follow-Up at Delivery and 6 and 14 Weeks Postpartum (Complementary Log-Log Regression Model)
| Baseline Model (N=404) | Final Model (N=404) | |||
|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | |||
| Delivery | 1 | 1 | ||
| 6 weeks postpartum | 0.21 (0.10, 0.43) | <.001 | 0.27 (0.10, 0.70) | <.001 |
| 14 weeks postpartum | 0.76 (0.49, 1.13) | .18 | 0.47 (0.22, 0.89) | .003 |
| Lives with partner/spouse/children | 1 | |||
| Lives by herself or with other relatives/friends | 0.74 (0.29, 1.65) | .50 | ||
| Not employed | 1 | 1 | ||
| Employed | 1.69 (1.07, 2.33) | .03 | 1.2 (0.81, 1.13) | .28 |
| Kisumu | 1 | |||
| Other | 1.22 (0.80, 1.73) | .35 | ||
| 14–28 weeks | 1 | |||
| 29–36 weeks | 1.08 (0.69, 1.58) | .73 | ||
| Total pregnancies, including current | 1.00 (0.90, 1.10) | .95 | ||
| No | 1 | |||
| Yes | 0.89 (0.47, 1.56) | .72 | ||
| <5 years | 1 | 1 | ||
| ≥5 years | 0.62 (0.39, 0.97) | .04 | 0.83 (0.49, 1.06) | .33 |
| Not disclosed | 1 | 1 | ||
| Disclosed | 0.68 (0.44, 1.00) | 0.05 | 0.93 (0.58, 1.09) | .68 |
| Does not know | 1 | 1 | ||
| Knows, partner positive | 0.62 (0.38, 0.96) | .03 | 0.81 (0.47, 1.06) | .27 |
| Knows, partner negative | 0.81 (0.45, 1.34) | .46 | 0.99 (0.54, 1.12) | .97 |
| Stigma score (16–64) at baseline | 1.01 (0.98, 1.04) | .57 | ||
| Depression score (10–60) at baseline | 1.02 (1.00, 1.03) | .046 | 1.00 (0.98, 1.00) | .55 |
| General health perception (0–100) at baseline | 0.98 (0.97, 0.99) | <.001 | 0.99 (0.98, 1.00) | .01 |
| Never | 1 | |||
| At least once | 1.33 (0.90, 1.81) | .15 | ||
| <1000 | 1 | |||
| ≥1000 | 1.02 (0.40, 1.86) | .96 | ||
| ≤350 | 1 | |||
| 351–500 | 0.70 (0.34, 1.33) | .30 | ||
| >500 | 0.81 (0.45, 1.36) | .47 | ||
| Naïve | 1 | |||
| Experienced | 0.80 (0.52, 1.17) | .26 | ||
| Control | 1 | 1 | ||
| Intervention | 0.22 (0.11, 0.46) | <.001 | 0.29 (0.12, 0.69) | <.001 |
| Delivery | 1 | 1 | ||
| 6 weeks postpartum * Intervention | 1.10 (0.21, 2.33) | .90 | 1.05 (0.22, 1.14) | .93 |
| 14 weeks postpartum * Intervention | 3.35 (2.19, 2.41) | <.001 | 1.86 (2.01, 1.14) | <.001 |
Abbreviations: ART, antiretroviral therapy; CD4, cluster of differentiation 4; CI, confidence interval; HR, hazard ratio.
Note: Both baseline and final models are controlled for age, education, and marital status. All baseline models were tested for interaction effect with the time variable. The time interaction effect is included only if it is significant (P<.05). Final model comprised of variables that were significant in the baseline models.
Uptake of EID, HIV Status, HIV Incidence, and Predictors of HIV Infection Among Infants
| Intervention n/N (%) | Control n/N (%) | ||
|---|---|---|---|
| EID conducted | 181/195 (92.8) | 128/188 (68.1) | <.001 |
| EID conducted within 8 weeks | 145/181 (80.1) | 104/128 (81.2) | .25 |
| HIV negative | 174/181 (96.1) | 125/127 (98.4) | |
| HIV positive | 7/181 (3.9) | 2/127 (1.6) | .80 |
Abbreviations: EID, early infant diagnosis; PCR, polymerase chain reaction.
Assessed among those who were followed until 14 weeks postpartum, excluding 17 women with stillbirths and 4 women whose infant died before reaching 6 weeks postpartum who did not need to return for EID.
Assessed among infants who were tested for HIV.
Assessed among those for whom PCR test results were available.
HIV Incidence Rate by Study Group
| Total Infants | Total Incidents | Total Infant Weeks | Incidence Rate/100 Infant-Weeks (95% CI) | |
|---|---|---|---|---|
| Control | 181 | 2 | 962 | 0.21 (0.05, 0.83) |
| Intervention | 127 | 7 | 1333 | 0.53 (0.25, 1.10) |
| Total | 308 | 9 | 2295 | 0.39 (0.20, 0.75) |
Abbreviation: CI, confidence interval.
Determinants of HIV Infection Among Exposed Infants (Binary Logistic Regression Model)
| Adjusted OR (95% CI) | ||
|---|---|---|
| Naïve | Ref | |
| Experienced | 1.90 (0.39, 9.15) | .42 |
| 14–28 weeks | Ref | |
| 29–36 weeks | 0.57 (0.06, 5.22) | .62 |
| Home | Ref | |
| Institutional | 0.61 (0.05, 7.64) | .70 |
| Mixed or complementary feeding | Ref | |
| Exclusive breastfeeding | 0.26 (0.02, 3.00) | .28 |
| ≤90% or less | Ref | |
| >90% | 0.20 (0.04, 0.99) | .05 |
| Control | Ref | |
| Intervention | 6.43 (0.70, 59.44) | .10 |
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; OR, odds ratio.
Note: Regression model is adjusted for mother's age and education.
Uptake of Maternal and Child Health Services and Infant HIV PCR testing
| Intervention n/N (%) | Control n/N (%) | Unadjusted RRR (95% CI) | ||
|---|---|---|---|---|
| 50% or less of required ANC visits | 60/187 (32.1) | 81/182 (44.5) | 0.88 (0.80, 0.98) | |
| 51%–75% of required ANC visits | 25/187 (13.4) | 25/182 (13.7) | .03 | |
| 76%–100% of required ANC visits | 102/187 (54.6) | 76/182 (41.8) | ||
| 192/207 (92.8) | 181/196 (92.4) | .88 | 1.00 (0.95, 1.05) | |
| 42/207 (20.3) | 25/197 (12.7) | .04 | 0.93 (0.86, 1.00) | |
| 170/207 (82.1) | 139/197 (70.6) | .006 | 0.89 (0.82, 0.97) | |
| 188/197 (95.4) | 143/153(93.5) | .42 | 0.98 (0.93, 1.03) | |
| 156/160 (97.5) | 121/125 (96.8) | .72 | 1.01 (0.97, 1.05) |
Abbreviations: ANC, antenatal care; BCG, bacille Calmette-Guérin; CI, confidence interval; DPT, diphtheria, pertussis, and tetanus; PNC, postnatal care; RRR, relative risk ratio.
Chi-square test.
Assessed among those who required at least 1 ANC visit from the time of recruitment until delivery.
ANC package was considered complete if the following were done: hemoglobin, venereal disease research labs, blood group, and at least 1 urine test.
Assessed among those who were followed until delivery.
Full primary immunization was considered if the infant received BCG + polio at birth, and DPT + polio at 6, 10, and 14 weeks of age.